Circulating Tumor Cell Counts in Patients With Localized Prostate Cancer Including Those Under Active Surveillance

Overview

Journal In Vivo

Specialty Oncology

Date 2019 Sep 1

PMID 31471413

Citations 7

Authors

Se Young Choi

Bumjin Lim

Yoon Soo Kyung

Yunlim Kim

Bong Min Kim

Byung Hee Jeon

Jae Chan Park

Young Woong Sohn

Jae Hyuk Lee

Ji-Hyun Uh

Seongsoo Jang

Choung-Soo Kim

Affiliations

Soon will be listed here.

Abstract

Aim: To evaluate the clinical efficacy of a circulating tumor cell (CTC) test by comparison between healthy volunteers and patients with localized prostate cancer including those under active surveillance.

Materials And Methods: CTC counts in peripheral blood were compared between patients with prostate cancer (n=45) and healthy volunteers (n=17). CTCs were identified based on the expression of epithelial cell adhesion molecule (EpCAM) and counted using a SMART BIOPSY™ SYSTEM.

Results: The number of EpCAM+ cells was significantly higher in patients with cancer than in healthy volunteers. Among the low-risk patients (n=9), two had up-staging and six had up-grading. Among those up-staged, there was one case which was EpCAM Among those cases up-graded, three were EpCAM In those with stage T2 tumors, the presence of Gleason pattern 5 was positively correlated with EpCAM positivity (rho=0.59, p<0.001).

Conclusion: CTC counts in localized prostate cancer were associated with Gleason pattern 5. Active treatment should be considered for patients with low-risk disease during active surveillance who are found to have EpCAM+ CTCs because of a risk of up-staging and up-grading.

Citing Articles

Novel insights into biomarkers of progression in Desmoid tumor.

Liu B, Sun Z, Zhou R, Shen D, Zhu S, Chen L Front Oncol. 2023; 13:1206800.

PMID: 37601698 PMC: 10434506. DOI: 10.3389/fonc.2023.1206800.

Utilization of Circulating Tumor Cells in the Management of Solid Tumors.

Kurniali P, Storandt M, Jin Z J Pers Med. 2023; 13(4).

PMID: 37109080 PMC: 10145886. DOI: 10.3390/jpm13040694.

Insights into Circulating Tumor Cell Clusters: A Barometer for Treatment Effects and Prognosis for Prostate Cancer Patients.

Lu L, Hu W, Liu B, Yang T Cancers (Basel). 2022; 14(16).

PMID: 36010983 PMC: 9406494. DOI: 10.3390/cancers14163985.

A Systematic Review of Circulating Tumor Cells Clinical Application in Prostate Cancer Diagnosis.

Enikeev D, Morozov A, Babaevskaya D, Bazarkin A, Malavaud B Cancers (Basel). 2022; 14(15).

PMID: 35954464 PMC: 9367494. DOI: 10.3390/cancers14153802.

Prognostic Implications of Portal Venous Circulating Tumor Cells in Resectable Pancreatic Cancer.

Choi Y, Hong T, Yoon S, Lee I, Lee M, Choi H Biomedicines. 2022; 10(6).

PMID: 35740311 PMC: 9219704. DOI: 10.3390/biomedicines10061289.

References

de Bono J, Scher H, Montgomery R, Parker C, Miller M, Tissing H . Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008; 14(19):6302-9. DOI: 10.1158/1078-0432.CCR-08-0872. View

Lu S, Tsai W, Chang Y, Chou T, Pang S, Lin P . Identifying cancer origin using circulating tumor cells. Cancer Biol Ther. 2016; 17(4):430-8. PMC: 4910938. DOI: 10.1080/15384047.2016.1141839. View

Wan L, Pantel K, Kang Y . Tumor metastasis: moving new biological insights into the clinic. Nat Med. 2013; 19(11):1450-64. DOI: 10.1038/nm.3391. View

Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J . Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control. 2007; 19(2):175-81. PMC: 3064270. DOI: 10.1007/s10552-007-9083-8. View

Allard W, Matera J, Miller M, Repollet M, Connelly M, Rao C . Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004; 10(20):6897-904. DOI: 10.1158/1078-0432.CCR-04-0378. View

Komisarenko M, Martin L, Finelli A . Active surveillance review: contemporary selection criteria, follow-up, compliance and outcomes. Transl Androl Urol. 2018; 7(2):243-255. PMC: 5911534. DOI: 10.21037/tau.2018.03.02. View

Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B . Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res. 2007; 13(3):920-8. DOI: 10.1158/1078-0432.CCR-06-1695. View

Hugosson J, Carlsson S . Overdetection in screening for prostate cancer. Curr Opin Urol. 2014; 24(3):256-63. DOI: 10.1097/MOU.0000000000000054. View

Stamey T, Caldwell M, McNeal J, Nolley R, Hemenez M, Downs J . The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?. J Urol. 2004; 172(4 Pt 1):1297-301. DOI: 10.1097/01.ju.0000139993.51181.5d. View

10.

Russo G, Bier S, Hennenlotter J, Beger G, Pavlenco L, van de Flierdt J . Expression of tumour progression-associated genes in circulating tumour cells of patients at different stages of prostate cancer. BJU Int. 2018; 122(1):152-159. DOI: 10.1111/bju.14200. View

11.

Esmaeilsabzali H, Beischlag T, Cox M, Dechev N, Parameswaran A, Park E . An integrated microfluidic chip for immunomagnetic detection and isolation of rare prostate cancer cells from blood. Biomed Microdevices. 2016; 18(1):22. DOI: 10.1007/s10544-016-0041-7. View

12.

Soletormos G, Semjonow A, Sibley P, Lamerz R, Petersen P, Albrecht W . Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice. Clin Chem. 2005; 51(8):1342-51. DOI: 10.1373/clinchem.2004.046086. View

13.

Bravaccini S, Puccetti M, Bocchini M, Ravaioli S, Celli M, Scarpi E . PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis. Sci Rep. 2018; 8(1):4254. PMC: 5844862. DOI: 10.1038/s41598-018-22594-1. View

14.

Todenhofer T, Park E, Duffy S, Deng X, Jin C, Abdi H . Microfluidic enrichment of circulating tumor cells in patients with clinically localized prostate cancer. Urol Oncol. 2016; 34(11):483.e9-483.e16. DOI: 10.1016/j.urolonc.2016.06.004. View

15.

Carroll P, Mohler J . NCCN Guidelines Updates: Prostate Cancer and Prostate Cancer Early Detection. J Natl Compr Canc Netw. 2018; 16(5S):620-623. DOI: 10.6004/jnccn.2018.0036. View

16.

Masuda T, Hayashi N, Iguchi T, Ito S, Eguchi H, Mimori K . Clinical and biological significance of circulating tumor cells in cancer. Mol Oncol. 2016; 10(3):408-17. PMC: 5528976. DOI: 10.1016/j.molonc.2016.01.010. View

17.

Suh Y, Joung J, Kim S, Seo H, Chung J, Lee K . Establishment and Application of Prostate Cancer Circulating Tumor Cells in the Era of Precision Medicine. Biomed Res Int. 2017; 2017:7206307. PMC: 5694577. DOI: 10.1155/2017/7206307. View

18.

Sun Y, Yang X, Zhou J, Qiu S, Fan J, Xu Y . Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance. J Cancer Res Clin Oncol. 2011; 137(8):1151-73. DOI: 10.1007/s00432-011-0988-y. View

19.

Thalgott M, Rack B, Maurer T, Souvatzoglou M, Eiber M, Kress V . Detection of circulating tumor cells in different stages of prostate cancer. J Cancer Res Clin Oncol. 2013; 139(5):755-63. DOI: 10.1007/s00432-013-1377-5. View

20.

Meyer C, Pantel K, Tennstedt P, Stroelin P, Schlomm T, Heinzer H . Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer. Urol Oncol. 2016; 34(5):235.e11-6. DOI: 10.1016/j.urolonc.2015.12.003. View